Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 39.13 GBp
Change Today 0.00 / 0.00%
Volume 14.0K
ETX On Other Exchanges
Symbol
Exchange
London
Berlin
As of 11:30 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

e-therapeutics plc (ETX) Snapshot

Open
39.13 GBp
Previous Close
39.13 GBp
Day High
39.13 GBp
Day Low
39.13 GBp
52 Week High
02/26/15 - 49.00 GBp
52 Week Low
01/7/15 - 26.00 GBp
Market Cap
103.5M
Average Volume 10 Days
49.5K
EPS TTM
-0.03 GBp
Shares Outstanding
264.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for E-THERAPEUTICS PLC (ETX)

Related News

No related news articles were found.

e-therapeutics plc (ETX) Related Businessweek News

No Related Businessweek News Found

e-therapeutics plc (ETX) Details

e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology. The company focuses on the discovery of drugs for cancer and central nervous system disorders. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; and ETS6103, a Phase IIb trial product for depressive disorders. The company also focuses on developing ETX1153c for the treatment of clostridium difficile. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

26 Employees
Last Reported Date: 05/7/15
Founded in 2001

e-therapeutics plc (ETX) Top Compensated Officers

Founder, Acting Chairman, Chief Executive Off...
Total Annual Compensation: 466.0K GBP
Chief Financial Officer, Finance Director and...
Total Annual Compensation: 156.0K GBP
Development Director and Executive Director
Total Annual Compensation: 284.0K GBP
Compensation as of Fiscal Year 2015.

e-therapeutics plc (ETX) Key Developments

e-Therapeutics plc announces Progress in ETS2101 Phase Ib Study

e-Therapeutics plc announced that the first patient has been enrolled into its phase 1b programme for its cancer drug, ETS2101. The first patient received the initial dose on 19 May and will be included in the cohort investigating the safety, tolerability and anti-tumour activity of ETS2101 in patients with newly-diagnosed hepatocellular carcinoma (HCC), in combination with standard of care, sorafenib. As part of this programme of work, in addition to newly-diagnosed HCC, e-Therapeutics will be investigating ETS2101 in combination with the standard of care for patients with newly-diagnosed pancreatic cancer (gemcitabine plus nab-paclitaxel), and as a monotherapy in patients with primary HCC or pancreatic cancer who have relapsed or refractory disease. The Phase Ib trial commencing now is designed to explore the safety, dosing and activity of ETS2101 both in monotherapy and in combination with standard of care treatment in HCC and pancreatic cancer.

e-Therapeutics plc., Annual General Meeting, Jun 11, 2015

e-Therapeutics plc., Annual General Meeting, Jun 11, 2015., at 10:30 GMT Standard Time. Location: Bond Dickinson LLP, St Ann's Wharf.

e-Therapeutics plc announces Consolidated Earnings Results Full Year Results for the Year Ended January 31, 2015 and Company Cash Flows Results for the Year Ended January 31, 2015

e-Therapeutics plc announced consolidated earnings results full year results for the year ended January 31, 2015 and company cash flows results for the year ended January 31, 2015. For the year, on group basis, the company reported operating loss of £10,175,000 against £6,719,000 a year ago. Loss before tax was £9,818,000 against £6,102,000 a year ago. Loss for the year attributable to equity holders of the company was £7,777,000 or 2.94 pence per basic and diluted share against £5,039,000 or 1.98 pence per basic and diluted share a year ago. Net cash from operating activities was £9,855,000 against £5,720,000 a year ago. Acquisition of property, plant and equipment was £31,000 against £22,000 a year ago. Acquisition of other intangible assets was £158,000 against £150,000 a year ago. For the year, on company basis, the company’s net cash from operating activities was £9,855,000 against £5,720,000 a year ago. Acquisition of property, plant and equipment was £31,000 against £22,000 a year ago. Acquisition of other intangible assets was £158,000 against £150,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETX:LN 39.13 GBp 0.00

ETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETX.
View Industry Companies
 

Industry Analysis

ETX

Industry Average

Valuation ETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.